

# CITATION REPORT

List of articles citing

Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxicam alone

DOI: [10.1002/art.1780381011](https://doi.org/10.1002/art.1780381011)

Arthritis and Rheumatism, 1995, 38, 1447-56.

Source: <https://exaly.com/paper-pdf/25839159/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
37	Tenidap in patients with rheumatoid arthritis. A 4-week, placebo-controlled study. <i>Scandinavian Journal of Rheumatology</i> , <b>1996</b> , 25, 345-51	1.9	5
36	Effects of tenidap on intracellular signal transduction and the induction of proinflammatory cytokines: a review. <i>General Pharmacology</i> , <b>1996</b> , 27, 943-56		17
35	Tenidap, a structurally novel drug for the treatment of arthritis: antiinflammatory and analgesic properties. <i>Inflammation Research</i> , <b>1996</b> , 45, 54-61	7.2	28
34	Tenidap in rheumatoid arthritis: comment on the article by Blackburn et al. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1263-4		
33	Anti-inflammatory and antipyretic analgesics and drugs used in gout. <i>Side Effects of Drugs Annual</i> , <b>1997</b> , 20, 86-102	0.2	
32	Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. <i>Drugs</i> , <b>1997</b> , 53, 337-48	12.1	8
31	Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models. <i>Inflammation Research</i> , <b>1997</b> , 46, 168-79	7.2	7
30	Limitation of activity in an acute model of arthritis: effect of drug treatment. <i>Inflammation Research</i> , <b>1997</b> , 46, 491-5	7.2	7
29	Antifibroproliferative effect of tenidap in chronic antigen-induced arthritis. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 2147-56		8
28	Termination of acute-phase response: role of some cytokines and anti-inflammatory drugs. <i>General Pharmacology</i> , <b>1998</b> , 31, 9-18		56
27	A comparison of the disease-modifying and cytokine-regulating activities of tenidap, piroxicam and cyclosporin-A using the adjuvant-induced model of arthritis in rats. <i>Inflammopharmacology</i> , <b>1998</b> , 6, 193-202	5.1	3
26	A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients. <i>Pharmaceutical Research</i> , <b>1999</b> , 16, 1608-15	4.5	2
25	Antimalarials for treating rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2000</b> ,	5.2	13
24	[Treatment of rheumatoid arthritis]. <i>Medicina Clínica</i> , <b>2000</b> , 114, 777-83	1	
23	Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review. <i>Clinical Therapeutics</i> , <b>2002</b> , 24, 1225-91	3.5	28
22	Guidelines for the management of rheumatoid arthritis: 2002 Update. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 328-46		1135
21	[Antimalarials: an update in rheumatic diseases]. <i>Reumatología Clínica</i> , <b>2006</b> , 2, 190-201	0.9	8

20	Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity. <i>The Cochrane Library</i> , <b>2011</b> , CD008952	5.2	13
19	Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2011</b> , 20, 1150-8	2.6	18
18	Anti-Cytokine Therapy for AA Amyloidosis. <b>2013</b> ,		1
17	Three component synthesis of 2-oxindole via sequential Michael addition, intramolecular cyclization and aromatization. <i>RSC Advances</i> , <b>2014</b> , 4, 18549	3.7	4
16	Drug-dendrimer supramolecular complexation studied from molecular dynamics simulations and NMR spectroscopy. <i>Structural Chemistry</i> , <b>2014</b> , 25, 1443-1455	1.8	12
15	Tenidap sodium. <b>2016</b> , 732-733		
14	Piroxicam. <b>2016</b> , 795-798		1
13	Anti-malarials: Are There Benefits Beyond Mild Disease?. <i>Current Treatment Options in Rheumatology</i> , <b>2016</b> , 2, 1-12	1.3	5
12	Nonsteroidal Anti-Inflammatory Therapy: A Journey Toward Safety. <i>Medicinal Research Reviews</i> , <b>2017</b> , 37, 802-859	14.4	59
11	Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study. <i>Drug Delivery and Translational Research</i> , <b>2017</b> , 7, 709-730	6.2	14
10	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. <i>European Journal of Clinical Pharmacology</i> , <b>2021</b> , 77, 13-24	2.8	9
9	Chemokine and Cytokine Modulators. <b>2003</b> , 119-192		1
8	Piroxicam. <b>2006</b> , 2843-2845		
7	Tenidap sodium. <b>2006</b> , 3313-3314		
6	Tenidap. <b>2007</b> , 1-4		
5	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs). <b>2010</b> , 223-369		
4	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. <i>Systematic Reviews</i> , <b>2021</b> , 10, 294	3	0
3	Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis. <b>2008</b> , 5-36		1

2 Regioselective One-Pot Synthesis and Antioxidant Activity Study of Trichloro Isatins and Dichloro Isatins. *Polycyclic Aromatic Compounds*, 1-11 1.3

1 Design and synthesis optimization of novel diimide indoles derivatives for ameliorating acute lung injury through modulation of NF- $\kappa$ B signaling pathway. **2023**, 106557 0